The National Drug Crisis - What Have We Learned from the Regional Science Disciplines?

被引：0

作者：

Cushing, Brian J. ^{[1
]}

Erfanian, Elham ^{[2
]}

Peters, David ^{[3
]}

机构：

[1] West Virginia Univ, Dept Econ, Morgantown, WV 26506 USA

[2] Univ Kentucky, Dept Agr Econ, Lexington, KY 40506 USA

[3] Iowa State Univ, Dept Sociol, Ames, IA USA

来源：

REVIEW OF REGIONAL STUDIES | 2020年 / 50卷 / 03期

关键词：

regional; rural; mortality; drug crisis; MORTALITY; OVERDOSE; ALCOHOL; ILLICIT; DEATHS;

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

Brian Cushing's Presidential Address for the Southern Regional Science Association (Cushing, 2017) detailed the U.S. drug crisis, including the high cost in terms of lost lives and financial costs. After determining almost no participation in drug crisis research by the regional science community, he charged regional scientists to learn about the crisis and become part of the discussion. In the few years since that address, the drug crisis has continued to accelerate. This time, however, regional science scholars have stepped up to conduct research and become part of the policy discussions. We update Cushing's (2017) discussion with new details regarding the worsening crisis. We then document and discuss the "regional science" contributions to the ongoing drug crisis literature. We finish with thoughts regarding what regional scientists doing research on the drug crisis should consider going forward.

引用

页码：353 / 382

页数：30

共 50 条

[31] Damage in lupus patients-what have we learned so far? [J].

Eder, L. ;

Urowitz, M. B. ;

Gladman, D. D. .

LUPUS, 2013, 22 (12) :1225-1231

[32] Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand [J].

Cavallari, Ilaria ;

Maddaloni, Ernesto .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (04)

[33] What Have We Learned About Influenza Deaths in Children and How Can We Do Better? [J].

Edwards, Kathryn M. .

PEDIATRICS, 2018, 141 (04)

[34] Mortality within 30 days of receiving systemic anti-cancer therapy at a regional oncology unit: What have we learned? [J].

Yoong, Jaclyn ;

Seah, Jo-An ;

Hamilton, Katherine ;

Teo, Lee Na ;

Chong, Geoffrey .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (04) :325-329

[35] The MELD Scoring System and the Prediction of Outcomes in Heart Failure Patients What We Have Learned From the Hepatologists [J].

Eisen, Howard J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (22) :2262-2263

[36] Topical corticosteroids in bullous pemphigoid: What we have learned after two decades [J].

Joly, P. ;

Tedbirt, B. .

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2022, 149 (02) :79-80

[37] Liver cancer mortality over six decades in an epidemic area: what we have learned [J].

Chen, Jian-Guo ;

Zhu, Jian ;

Zhang, Yong-Hui ;

Chen, Yong-Sheng ;

Lu, Jian-Hua ;

Zhu, Yuan-Rong ;

Chen, Hai-Zhen ;

Shen, Ai-Guo ;

Wang, Gao-Ren ;

Groopman, John D. ;

Kensler, Thomas W. .

PEERJ, 2021, 9

[38] The Critically Ill Pediatric Hematopoietic Stem Cell Transplant Patient: What Have We Learned? [J].

Hsing, Deyin D. ;

Howell, Joy D. ;

Greenwald, Bruce M. .

PEDIATRIC CRITICAL CARE MEDICINE, 2013, 14 (03) :326-328

[39] Advances in clinical outcomes: What we have learned during the COVID-19 pandemic [J].

Al-Musa, Amer ;

LaBere, Brenna ;

Habiballah, Saddiq ;

Nguyen, Alan A. ;

Chou, Janet .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) :569-578

[40] What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? [J].

Moe, Sharon M. ;

Thadhani, Ravi .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (06) :651-655

← 1 2 3 4 5 →